Suppliers and packagers for VYONDYS 53

VYONDYS 53

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sarepta Theraps Inc	VYONDYS 53	golodirsen	SOLUTION;INTRAVENOUS	211970	NDA	Sarepta Therapeutics, Inc.	60923-465-02	1 VIAL, SINGLE-USE in 1 CARTON (60923-465-02) / 2 mL in 1 VIAL, SINGLE-USE	2019-12-12

Vyondys 53 (golodirsen) supplier landscape: manufacturers, label and private-label roles, and key dependency risks

Last updated: May 27, 2026

Vyondys 53 (golodirsen) is a single-source supply chain anchored on Sarepta Therapeutics. Public contracting and manufacturing disclosures indicate Sarepta controls critical upstream dependencies through its internal biologics capability and through fill-finish and logistics partners used for commercial supply. For sourcing and IP risk management, the practical question is which steps in the supply chain are truly fungible: drug substance manufacturing (DUS), drug product fill-finish (DP), cold-chain distribution, and specialty channel fulfillment.

Who supplies Vyondys 53 (golodirsen) drug substance and drug product?

Short answer: Sarepta is the primary supplier and market authorization holder for Vyondys 53 and typically directs both drug substance and drug product supply using its manufacturing network plus contract manufacturing organizations (CMOs) for specific unit operations such as sterile fill-finish and packaging.

What entities are linked to Vyondys 53 supply in common public filings?

• Sarepta Therapeutics (U.S.): sponsor and commercial manufacturer-of-record for Vyondys 53; controls release strategy and supply planning.
• Specialty CMOs for sterile fill-finish: used for drug product manufacturing, which for oligonucleotide therapeutics often includes sterile handling, fill, labeling, and packaging.
• Cold-chain logistics providers: used for distribution because golodirsen is administered as an IV infusion and requires temperature-controlled shipping.

Key procurement implication: even if “multiple suppliers” appear in distribution layers (3PLs, couriers, specialty wholesalers), the bottleneck is usually sterile fill-finish capacity and oligonucleotide drug substance control, which are less interchangeable than logistics.

Which companies are responsible for Vyondys 53 distribution and specialty pharmacy fulfillment?

Short answer: distribution is routed through specialty channels that stock or dispense high-cost injectables, with Sarepta or its logistics partners coordinating cold-chain shipments and specialty pharmacy fulfillment.

Typical roles in the Vyondys 53 specialty channel

• Sarepta or its logistics agent: manages order fulfillment scheduling, temperature control parameters, and shipment release.
• Specialty pharmacies: dispense to neuromuscular clinics and hospitals, often coordinating infusion scheduling with patients.
• Wholesalers/3PLs: provide warehousing and transportation for time- and temperature-sensitive products.

Key procurement implication: supplier diversification in this layer matters less for drug continuity than manufacturing release availability. The supply interruption risk usually originates at release testing, aseptic fill-finish, or drug substance lot readiness.

How do Vyondys 53 supply constraints compare with competing DMD antisense oligonucleotides?

Short answer: supply chain fragility depends on whether the competitor shares platform CMC capabilities, uses the same CMO ecosystem, or relies on the same fill-finish network for sterile final product.

Comparison lens used by procurement and continuity teams

• Drug substance manufacturing capacity: oligonucleotide synthesis and purification are the long lead pole.
• Sterile fill-finish throughput: aseptic processing and lot release testing often determine real-world availability.
• Analytical release testing: release assays for identity, purity, and potency gate lot release.
• Cold-chain packaging: insulated shippers and qualified temperature mapping can constrain throughput during demand spikes.

Key procurement implication: when competing DMD oligonucleotides use the same fill-finish CMO or shared analytical platforms, “separate suppliers” do not fully eliminate continuity risk.

What are the key manufacturing steps in Vyondys 53 supply, and which are hardest to dual-source?

Short answer: oligonucleotide drug substance and sterile fill-finish are typically the least dual-source-friendly steps.

Drug substance (DUS) dependency points

• Synthesis and purification: oligonucleotide production is equipment- and process-specific.
• Quality system controls: raw material qualification and in-process controls are not trivially transferable.
• Analytical methods: assay transfer and validation take time.

Drug product (DP) dependency points

• Aseptic fill-finish: sterility assurance process validation and equipment qualification are gating items.
• Component sourcing: vials, stoppers, seals, and sterile water components can create secondary constraints.
• Packaging and cold-chain shipping configuration: time-temperature studies and labeling coordination.

Batch release and supply continuity

• Release testing capacity: assay execution and documentation workload can bottleneck.
• Stability and shelf-life verification: changes require bridging studies or re-approval.

What FDA-regulated manufacturing controls affect who can supply Vyondys 53?

Short answer: only facilities listed or approved for the manufacturing steps in regulatory filings can supply the commercial product at market scale.

Regulatory control points that limit substitution

• GMP compliance and inspection history
• Registered manufacturing sites for drug substance and drug product
• Release testing and specification conformance
• CMC comparability requirements for site changes

Key procurement implication: even if alternate suppliers can manufacture golodirsen, they cannot supply the FDA-cleared product stream without validated CMC transfer and approved site listings.

How can buyers map “true suppliers” versus channel partners for Vyondys 53?

Short answer: segment the supply chain into (1) manufacturing of drug substance, (2) manufacturing of drug product and release, (3) specialty distribution and infusion supply chain.

Supplier map template (procurement-ready)

1. Drug substance manufacturer(s)
   • Look for: site-specific GMP references in regulatory CMC sections and sponsor manufacturing descriptions.
2. Drug product fill-finish manufacturer(s)
   • Look for: sterile fill and labeled-packaging responsibilities.
3. Release testing and QA batch release
   • Look for: whether release is internal to Sarepta or performed under contract.
4. Cold-chain logistics and specialty pharmacy fulfillment
   • Look for: temperature-controlled shipment capabilities and lead-time SLAs.

Does Vyondys 53 have generic or biosimilar sourcing that affects supplier competition?

Short answer: as of the latest public information, Vyondys 53 is an FDA-approved antisense oligonucleotide with market exclusivity dynamics that have historically limited generic substitutes; supplier competition is therefore mainly within the brand’s own manufacturing ecosystem rather than interchangeable multisource products.

Practical impact for procurement

• Substitution risk is primarily manufacturing continuity risk (lot availability) rather than price competition from generics.
• Contract negotiations are mostly for capacity and lead time, not for multiple “approved alternatives” that pharmacists can substitute at point of dispensing.

Key Takeaways

• Sarepta is the central supplier entity for Vyondys 53, controlling drug supply continuity through its manufacturing network and oversight of CMOs used for specific CMC steps.
• True sourcing constraints sit at drug substance synthesis and sterile fill-finish, not at the specialty pharmacy distribution layer.
• Diversification within logistics and distribution channels does not remove the bottleneck if sterile DP capacity or DUS readiness is the gating factor.
• Regulatory site approval and CMC comparability are the primary barriers to rapid dual-sourcing.

FAQs

1. What is the difference between Vyondys 53 logistics suppliers and manufacturing suppliers?
   Logistics suppliers move and warehouse temperature-controlled shipments, while manufacturing suppliers produce drug substance or sterile drug product under GMP with FDA-cleared site responsibilities.

2. Can a different CMO supply Vyondys 53 if Sarepta changes manufacturing sites?
   Only after CMC site transfer, process validation, and FDA acceptance for the relevant manufacturing steps.

3. What tends to cause Vyondys 53 backorders: manufacturing or distribution?
   Backorders usually track drug substance and sterile fill-finish lot readiness and release testing capacity, with distribution constraints acting as secondary contributors.

4. Are there multiple approved versions of golodirsen that diversify sourcing?
   Procurement substitution is constrained unless FDA-approved alternatives exist with interchangeability at dispensing. For antisense oligonucleotides, this is rarely immediate.

5. How should hospitals evaluate supply reliability for Vyondys 53?
   Focus on lot release lead times, cold-chain capability, sterile fill-finish capacity continuity, and QA release throughput, not only on who delivers the product.

References

1. FDA Orange Book database. (accessed via public FDA listings).
2. FDA prescribing information for Vyondys 53 (golodirsen). (accessed via FDA label documents).
3. Sarepta Therapeutics corporate materials and SEC filings referencing manufacturing and supply chain (accessed via SEC EDGAR).